The aim of this article is to evaluate the ratio of expenditures between fundamental research, applied research and technological development, to analyse this proportion in the innovation processes of Estonian biotech public sector and private SMEs, and to shape supportive measures to knowledge...

Are IPRs institutions meant to foster innovative activities or conversely to secure appropriation and profitability? Taking stock of a long-term empirical evidence on the pharmaceutical sector in the US, we can hardly support IPRs intended as an innovation rewarding institution. According to our...

Die im GKV-Finanzstabilisierungsgesetz verankerten Änderungen der Rahmenbedingungen für die Erstattungsbetragsverhandlungen innovativer Arzneimittel werden als Gefahr für die zukünftige Versorgung der Patienten und für den Forschungs- und Produktionsstandort gesehen. Die neuen Leitplanken...

This paper analyzes M&A patterns of R&D projects in the antidiabetics industry. For this purpose, we construct a database with all corporate individual antidiabetics R&D projects over the period 1997 - 2017, and add detailed information on firms' technology dimension using patent information,...

In the literature, it is widely discussed whether the pharmaceutical industry is going through an innovation crisis. Unfortunately, no comprehensive review exists to date that outlines the main empirical findings. In this paper, we provide an extensive survey on what is currently known about the...

The main aim of this paper is to study innovative activity, as measured by patent indicators, in pharmaceutical and biotechnological sectors in the Nordic Countries. The biotech sector in general and pharmaceutical in particular is one of the areas selected for strategic investments in every...

We examine the relationship between the characteristics of the firms' knowledge base in terms of knowledge capital and knowledge integration and the stock market value of 99 firms active in biotechnology during the nineties. Panel data regression models show that our measure of knowledge...

This paper investigates the institutional and organizational sources of change and persistence in the technological systems which bring new products to market in the Chinese pharmaceutical industry. Even after fifteen years of economic reforms, research institutes, manufacturers and wholesalers...

Does a firm engage in a joint venture with a technologically advanced foreign partner to complement or substitute investments in its own technological capabilities? We address this question in a comparative study of 222 Chinese pharmaceutical manufacturers and Sino-foreign joint ventures. A...

During the past 20 years, the world pharmaceutical industry has experienced a dramatic increase in R&D intensity. We apply and extend a model developed by Grabowski and Vernon (2000) with a pooled data sample of the 15 publicly listed Japanese drug firms for the period 1987 to 1998. As in the...